COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,544 Articles (22,881 medRxiv, 8,663 bioRxiv)

Most recent first Previous |  Page 494: Articles 4931-4940  | Next

Sociodemographic inequity in COVID-19 vaccine uptake among youth in Zimbabwe
Larsson, L. S., Dziva Chikwari, C., Simms, V., Tembo, M., Mahomva, A., Mugurungi, O., Hayes, R., Mackworth-Young, C., Bernays, S., Mavodza, C., Taruvinga, T., Bandason, T., Dauya, E., Ferrand, R., Kranzer, K.
10.1101/2023.03.10.23287107 — Posted: 2023-03-10
Assessing the utility of COVID-19 case reports as a leading indicator for hospitalization forecasting in the United States
Reich, N. G., Wang, Y., Burns, M., Ergas, R., Cramer, E. Y., Ray, E. L.
10.1101/2023.03.08.23286582 — Posted: 2023-03-10
Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
Hladish, T. J., Pillai, A. N., Pearson, C. A. B., Toh, K. B., Tamayo, A., Stoltzfus, A., Longini, I.
10.1101/2023.03.09.23285319 — Posted: 2023-03-10
Prevalence of IgG and IgM to SARS-CoV-2 and other human coronaviruses in The Democratic Republic of Congo, Sierra Leone and Uganda: A Longitudinal Study
Gallagher, K. E., Lawal, B. J., Kitonsa, J., Tindanbil, D., Kasonia, K., Drammeh, A., Lowe, B., Mukadi-Bamuleka, D., Patterson, C., Greenwood, B., Samai, M., Leigh, B., Tetteh, K. A., Ruzagira, E., Watson-Jones, D., Kavunga-Membo, H.
10.1101/2023.03.08.23286979 — Posted: 2023-03-10
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
Drysdale, M., Gibbons, D. C., Singh, M., Rolland, C., Lavoie, L., Skingsley, A., Lloyd, E. J.
10.1101/2023.03.09.23287034 — Posted: 2023-03-10
Integrated analyses of single-cell RNA-seq public data reveal the gene regulatory network landscape of respiratory epithelial and peripheral immune cells in COVID-19 patients
Zhang, L., Nishi, H., Kinoshita, K.
10.1101/2023.03.09.23287043 — Posted: 2023-03-10
Medium-term scenarios of COVID-19 as a function of immune uncertainties and chronic disease
Saad-Roy, C. M., Morris, S. E., Baker, R. E., Farrar, J., Graham, A. L., Levin, S. A., Wagner, C. E., Metcalf, C. J. E., Grenfell, B. M.
10.1101/2023.03.08.23287004 — Posted: 2023-03-10
Clinical performance of a chemiluminescence SARS-CoV-2 antibody assay in a cohort of healthcare workers, blood donors and COVID-19 patients.
Rangel, G. A., Lopez, D., Chavarria, A., Mudarra, L., Britton, G. B., Villarreal, A. E.
10.1101/2023.03.09.23287052 — Posted: 2023-03-10
A single C-terminal residue controls SARS-CoV-2 spike trafficking and virion assembly
Dey, D., Qing, E., He, Y., Chen, Y., Jennings, B., Cohn, W., Singh, S., Gakhar, L., Schnicker, N. J., Pierce, B. G., Whitelegge, J. P., Doray, B., Orban, J. P., Gallagher, T., Hasan, S. S.
10.1101/2023.03.09.531992 — Posted: 2023-03-10
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that bind a conserved membrane proximal epitope of the spike
De Cae, S., Van Molle, I., van Schie, L., Shoemaker, S. R., Deckers, J., Debeuf, N., Lameire, S., Nerinckx, W., Roose, K., Fijalkowska, D., Devos, S., Desmet, A.-S., Zavala Marchan, J. C., Venneman, T., Ghassabeh, G. H., Sedeyn, K., Ballegeer, M., Vanheerswynghels, M., De Wolf, C., Demol, H., Vanhaverbeke, P., Lonigro, C., Bockstal, V., Rinaldi, M., Abdelnabi, R., Neyts, J., Marqusee, S., Lambrecht, B. N., Callewaert, N., Remaut, H., Saelens, X., Schepens, B.
10.1101/2023.03.10.531533 — Posted: 2023-03-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).